SAN DIEGO, CA – December 8, 2015 – BioAtla® LLC, a biotechnology company focused on the development of Conditionally Active Biologic antibody therapeutics, today announced that it has entered into a license and option agreement with Pfizer Inc. to advance the development and commercialization of a new class of antibody therapeutics based on BioAtla®’s CAB platform and utilizing Pfizer’s proprietary antibody drug conjugate payloads.
Under the agreement, BioAtla® and Pfizer will each have a license to the other’s respective technology to pursue the development and commercialization of several CAB-ADC antibodies.
CAB-ADC antibodies aim to address the inherent limitations of current ADC antibody technology by actively binding to antigens expressed on tumort issue-resident cancer cells, but not to the same antigens expressed on normal cells in non-diseased tissues.
The use of CAB antibodies as payload delivery vehicles could dramatically increase the number of tumor-associated antigens that are addressable with ADC technology.
CAB proteins can be generated in several different formats including naked monoclonal antibodies, antibody drug conjugates, immune checkpoint inhibitors, bispecific antibodies, and chimeric antigen receptor T cells.
The CAB antibody’s selective activation results from amino acid substitutions of human-like sequences made to ensure compatibility.
Reliably good expression and high manufacturing yields are also derived from BioAtla®’s patented Comprehensive Integrated Antibody Optimization™ technology that allows every step of development and screening of antibody variants through final CAB lead selection to be conducted in the mammalian cell type to be used in manufacturing.